Latest presentation, page-49

Delays at a corporate level are part of every business - Firstly although the information has come from those that attended the conference we have no idea of what exactly is going on with BBI and what the delays may be - The data has been successfully generated for BBI and this has an intangible value to ADO as a company as they now have data of value that could be very valuable if handed to one of BBI's competitors - This is why IPO or not etc etc the deal will go ahead with Anteo

ADO is also in a very different position to other biotech companies in that it is not reliant on a binary event for drug trials etc - ADO has a large pipeline of testing customers of which a good amount are very close to signing.IMO

It would be a different story if we were trading at 25cents and BBI delayed as that would have been starting to price in part of that deals future income - We are now back at $110m mcap and have IMO very solid confirmation that POC1/GHC is looking at a 3-5 year partnership and have had a piece of equipment custom made to work alongside them - These developments are recent and add significant value and future value for the company.

I am still of the belief we will have more new deals to discuss and enjoy before the end of this year